Skip to content
RANIRani Therapeutics Holdings, Inc.

Earnings

When Rani Therapeutics Holdings, Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 25, after the close

Thu, Mar 25, 2027in 127 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 18 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$1.46M
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 +893.0%, Q4 2025 +42.1%
Net income
-$10.31M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$1.71MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 9, 2026, after the closeThe release
    Revenue
    $1.71M
    —
    Net income
    -$7.73M
    N/M
    EPS
    -$0.04
    N/M
    On November 9, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the three and nine months ended September 30, 2026.
  2. Q2 2026Aug 13, 2026, after the closeThe release+0.1%by the close of Aug 14
    Revenue
    $1.71M
    —
    Net income
    -$7.39M
    N/M
    EPS
    -$0.04
    N/M
  3. Q1 2026May 15, 2026, after the closeThe release11.0%by the close of May 18
    Revenue
    $1.71M
    +893.0%
    Net income
    -$7.03M
    N/M
    EPS
    -$0.04
    N/M
  4. Q4 2025Mar 26, 2026, after the closeThe release25.3%by the close of Mar 27
    Revenue
    $1.46M
    +42.1%
    Net income
    -$10.31M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 9, 2026 · after-hoursNov 9, 202640 d10-Q$1.71M—-$0.04—
Q2 2026Jun 30, 2026Aug 13, 2026 · after-hoursAug 13, 202644 d10-Q$1.71M—-$0.04+0.1%
Q1 2026Mar 31, 2026May 15, 2026 · after-hoursMay 15, 202645 d10-Q$1.71M+893.0%-$0.0411.0%
FY 2025
Q4 2025derivedDec 31, 2025Mar 26, 2026 · after-hoursMar 26, 202685 d10-K$1.46M+42.1%—25.3%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 6, 202537 d10-Q$0.00—-$0.1211.0%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 7, 202538 d10-Q$0.00—-$0.180.1%
Q1 2025Mar 31, 2025May 13, 2025 · after-hoursMay 13, 202543 d10-Q$172.00K—-$0.22+16.7%
FY 2024
Q4 2024derivedDec 31, 2024Mar 31, 2025 · after-hoursMar 31, 202590 d10-K$1.03M——2.4%
Q3 2024Sep 30, 2024Nov 14, 2024 · pre-marketNov 14, 202445 d10-Q$0.00—-$0.244.2%
Q2 2024Jun 30, 2024—Aug 6, 202437 d10-Q$0.00—-$0.26—
Q1 2024Mar 31, 2024May 6, 2024 · after-hoursMay 6, 202436 d10-Q$0.00—-$0.291.3%
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 9, 2026453872
10-QAug 13, 2026349245
10-QMay 15, 2026226703
10-KMar 26, 2026126417
10-QNov 6, 2025269774
10-QAug 7, 2025105045
10-QMay 13, 2025070382
10-KMar 31, 2025047740
10-QNov 14, 2024126763
10-QAug 6, 2024091793

Provenance

ProvenanceData status and checks

Rani Therapeutics Holdings, Inc. · CIK 1856725 · Engraved from SEC EDGAR